AG真人官方

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the company will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8鈥�10, 2025, at the Lotte New York Palace Hotel in New York City.

Dr. Richard Goldberg, Chief Development Officer, and Dr. Robin Taylor, Chief Commercial Officer, will participate in a fireside chat on Tuesday, September 9, 2025, to provide strategic insights on Agenus鈥� BOT/BAL immunotherapy program. The discussion will highlight recent pipeline progress, including the launch of the pivotal Phase 3 BATTMAN trial in metastatic colorectal cancer (mCRC), emerging BOT/BAL clinical data across treatment settings, updates on key partnerships, and anticipated milestones for the second half of 2025.

A live webcast of the fireside chat will be available via this .

A replay of the webcast will be accessible on the investors section of the Agenus website at following the event.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

View source version on businesswire.com:

Investors

917-362-1370

[email protected]



Media

781-674-4422

[email protected]

Source: Agenus, Inc.